Zacks: Galena Biopharma, Inc. (SLS) Given $9.00 Consensus Target Price by Brokerages

Galena Biopharma, Inc. (NYSE:SLS) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price target of $9.00 for the company and are expecting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also given Galena Biopharma an industry rank of 49 out of 256 based on the ratings given to its competitors.

Galena Biopharma stock traded down $0.02 during trading hours on Friday, reaching $1.40. 267,000 shares of the stock were exchanged, compared to its average volume of 191,094. Galena Biopharma has a twelve month low of $0.80 and a twelve month high of $11.09.

Galena Biopharma (NYSE:SLS) last posted its earnings results on Thursday, November 15th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12).

About Galena Biopharma

Develop biopharmaceuticals

Featured Article: Balance Sheet

Get a free copy of the Zacks research report on Galena Biopharma (SLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit